RBRiccardo Becchetti

Riccardo Becchetti

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Riccardo Becchetti has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Andrea Cappelleri

    Department of Veterinary Medicine and Animal Sciences, University of Milan, Lodi, Italy

    1 shared publication
  • Andrea Ponzetta

    Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden

    1 shared publication
  • Carmen Ghilardi

    Mario Negri Institute for Pharmacological Research IRCCS, Department of Experimental Oncology, Unit of Molecular Anti-Tumour Therapy, Milan, Italy

    1 shared publication
  • Claudia Nastasi

    LEO Foundation Skin Immunology Research Center, Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark

    1 shared publication
  • Cristina Matteo

    Laboratory of Cancer Pharmacology, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy

    1 shared publication
  • Eugenio Scanziani

    Department of Veterinary Medicine and Animal Sciences (DIVAS), University of Milan, Via dell'Università 6, Lodi 26900, Italy; Mouse and Animal Pathology Laboratory (MAPLab), Fondazione Unimi, Viale Ortles 22/4, Milan 20139, Italy

    1 shared publication

Latest Publications

  • Open Access

    Chemotherapy-induced neutropenia elicits metastasis formation in mice by promoting proliferation of disseminated tumor cells

    by Massimo Russo, Nicolò Panini, Paola Fabbrizio, Laura Formenti, Riccardo Becchetti, Cristina Matteo, Marina Meroni, Claudia Nastasi, Andrea Cappelleri, Roberta Frapolli, et al.

    Chemotherapy is the standard of care for most malignancies. Its tumor debulking effect in adjuvant or neoadjuvant settings is unquestionable, although secondary effects have been reported that paradoxically promote metastasis. Chemotherapy affects the hematopoietic precursors leading to myelosuppression, with neutropenia being the main hematological toxicity induced by cytotoxic therapy. We used renal and lung murine tumor models metastatic to the lung to study chemotherapy-induced neutropenia (CIN) in the metastatic process. Cyclophosphamide and doxorubicin, two myelosuppressive drugs, but not cisplatin, increased the burden of artificial metastases to the lung, by reducing neutrophils. This effect was recapitulated by treatment with anti-Ly6G, the selective antibody-mediated neutrophil depletion that unleashed the formation of lung metastases in both artificial and spontaneous metastasis settings. The increased cancer dissemination was reversed by granulocyte-colony stimulating factor-mediated boosting of neutrophils in combination with chemotherapy. CIN affected the early metastatic colonization of the lung, quite likely promoting the proliferation of tumor cells extravasated into the lung at 24–72 hours. CIN did not affect the late events of the metastatic process, with established metastasis to the lung, nor was there any effect on the release of cancer cells from the primary, whose growth was, in fact, somewhat inhibited. This work suggests a role of neutrophils associated to a common cancer treatment side effect and claims a deep dive into the relationship between chemotherapy-induced neutropenia and metastasis.